/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting
Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting

Research To Practice | Oncology Videos · Oct 12, 2026

Experts review advances in relapsed multiple myeloma, highlighting bispecifics, belantamab mafidotin combos, and novel oral CELMoDs.

Rechallenge Daratumumab Alongside Teclistamab in Patients Off Therapy for One Year

Patients previously exposed to daratumumab can successfully receive teclistamab combined with daratumumab if they have been off anti-CD38 therapy for at least a year. Faculty emphasize that this approach produces durable remissions despite limited representation in early registration trials.

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting thumbnail

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting

Research To Practice | Oncology Videos·a month ago

Biopsy Plasma Cells at Myeloma Relapse to Verify BCMA Expression Rather Than CD38

Clinicians can generally assume CD38 expression is maintained on myeloma cells without repeat testing. However, performing a bone marrow biopsy at relapse is critical to confirm BCMA expression and identify emerging resistance mechanisms before choosing BCMA-targeted engagers.

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting thumbnail

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting

Research To Practice | Oncology Videos·a month ago

Belantamab Mafodotin Succeeds After BCMA CAR-T Progression Because It Bypasses Host T-Cells

Belantamab mafodotin remains effective following BCMA CAR-T failure because antibody-drug conjugates do not depend on functional T cells for cytotoxicity. Moreover, rising soluble BCMA levels upon disease progression indicate that surface BCMA remains present and re-targetable.

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting thumbnail

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting

Research To Practice | Oncology Videos·a month ago

Extend Belantamab Mafodotin Dosing Intervals to Eight Weeks to Reverse Ocular Toxicity

Microcystic keratopathy from belantamab mafodotin involves superficial corneal epithelial changes rather than posterior chamber damage. Lengthening treatment intervals to every 8 to 12 weeks and delaying doses allows vision to recover while maintaining deep, MRD-negative therapeutic responses.

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting thumbnail

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting

Research To Practice | Oncology Videos·a month ago

Substitute H2 Receptor Antagonists for Proton Pump Inhibitors During Mezigdomide Therapy

Clinicians must avoid co-administering proton pump inhibitors with the novel CELMoD mezigdomide. When gastrointestinal acid suppression is indicated, treating teams should switch patients to H2 receptor blockers to prevent adverse drug interactions.

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting thumbnail

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting

Research To Practice | Oncology Videos·a month ago

CELMoDs Counteract T-Cell Exhaustion to Rescue Responses in Relapsed Multiple Myeloma

Beyond potent cereblon degradation, preclinical data indicate that mezigdomide stimulates T-cell activation and diminishes exhaustion. Reversing T-cell exhaustion offers a vital biological rationale for combining CELMoDs with bispecific antibodies or using them as bridging regimens.

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting thumbnail

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting

Research To Practice | Oncology Videos·a month ago

GPRC5D CAR-T Arlo-Cel Avoids Dysgeusia and Nail Toxicities Caused by Talquetamab

Despite directing therapy toward the same GPRC5D target, the CAR-T agent arlo-cel exhibits a markedly distinct tolerability profile compared to talquetamab. It spares patients the debilitating dysgeusia and dermatologic nail changes, presenting only low rates of cerebellar neurotoxicity.

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting thumbnail

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting

Research To Practice | Oncology Videos·a month ago